Succinic Acid Monoethyl Ester and Metformin Regulates Carbohydrate Metabolic Enzymes and Improves Glycemic Control in Streptozotocin-Nicotinamide Induced Type 2 Diabetic Rats

LEELAVINOTHAN PARI and RAMALINGAM SARAVANAN

Department of Biochemistry and Biotechnology, Faculty of Science, Annamalai University, Annamalainagar, Tamil Nadu, India.

Received September 9, 2005; Revised February 28, 2006; Accepted February 29, 2006

ABSTRACT

Objective. Succinic acid monoethyl ester (EMS) was recently proposed as an insulinotropic agent for the treatment of non-insulin dependent diabetes mellitus. In the present study the effect of EMS and Metformin on the activities of carbohydrate metabolic enzymes in streptozotocin–nicotinamide induced type 2 diabetic model was investigated. Methods. EMS were injected intraperitonially at doses 2, 4, and 8 µmol/g body weight (bw) respectively for 30 days, after which blood hemoglobin, glycosylated hemoglobin, plasma glucose and insulin, hexokinase, glucose-6-phosphatase, fructose-1, 6-bisphosphatase, glucose-6-phosphate dehydrogenase in liver and glycogen in liver and muscle were assayed. Results. Glucose, glycosylated hemoglobin, glucose-6-phosphatase and fructose-1,6-bisphosphatase were significantly increased and insulin, hemoglobin, hexokinase, glucose-6-phosphate dehydrogenase and glycogen were significantly decreased in diabetic rats. The enzyme activities were restored to the near normal levels in diabetic rats treated with EMS and Metformin. Conclusion. Our result suggest that non glucidic nutrient- EMS may act as a potent antidiabetic and insulinotropic agent by restoring the above biochemical alterations in streptozotocin -nicotinamide induced type 2 diabetes.

Keywords: Succinic Acid Monoethyl Ester, Nicotinamide, Metformin, Carbohydrate enzymes, Diabetes mellitus

Type 2 diabetes is a chronic metabolic disorder characterized by abnormalities in carbohydrate and lipid metabolism [1]. It represents a heterogeneous group of disorders having hyperglycemia, which is due to impaired carbohydrates (glucose) utilization resulting from a defective or deficient insulin secretory response. The liver plays a pivotal role in glucose and lipid homeostasis [2]. In experimental diabetes, enzymes of glucose metabolism are markedly altered and produce hyperglycemia, which leads to pathogenesis of diabetic complications [3]. Glucose homeostasis involves the coordinated regulation of several metabolic pathways including gluconeogenesis and glycolysis.

A number of therapeutic tools for the treatment of non-insulin dependent diabetes mellitus are currently available. A wide variety of structurally distinct molecules stimulate insulin secretion from pancreatic β cells by different mechanism of action. The ester carboxylic nutrient succinic acid (mono ethyl ester) derivative is a low toxicity drug (Fig 1) [5] and has attracted considerable interest for more than a decade as possible therapeutic agent for the treatment of type 2 diabetes. This is based on the ability of EMS to act as potent stimulator of insulin secretion. It has previously been shown that succinic acid ester can be taken up and metabolized by pancreatic β cells, leading to increased pro-insulin biosynthesis [6], insulin secretion and lower the blood glucose [7, 8]. Its ester also protects pancreatic islets in vivo and in vitro against diabetogenic agents streptozotocin [9], interleukin 1β [10], and nitric oxide donor (NO) [11]. EMS is a suitable nutrient both to cover the energy need of hepatocytes and act as a gluconeogenic precursors [12].
Generally non-glucidic nutrients control hyperglycemia, resulting in improved overall glycemic control in patients with type 2 diabetes. Metformin is an oral hypoglycemic agent, which belongs to the class known as the biguanides. Chemically it is N-N dimethylimidodicarbonimidic diamide [13]. Metformin is now widely used as one of the mainstays in the management of type 2 diabetes. Metformin reduces fasting plasma glucose concentration by reducing rate of hepatic glucose production via gluconeogenesis and glycogenolysis. Metformin improves glycemic control as monotherapy and in combination with other oral antidiabetic agents, such as sulfonylureas and thiazolidine diones [14].

To our knowledge there are no other available reports on the effect of nonglucidic nutrient EMS on enzymes of hepatic glucose metabolism in streptozotocin-nicotinamide induced type 2 diabetes. Therefore the aim of the present study was to explore the effect of EMS on key hepatic enzyme in diabetic rats. The effect of EMS was compared with conventional antidiabetic agent metformin.

**Materials and Methods**

**Drug and Chemicals**

Succinic acid monoethyl ester, and all other biochemicals and chemicals used in this experiment were purchased from Sigma chemical company Inc., St Louis, MO, USA. The chemicals were of analytical grade.

**Animals**

Healthy male albino Wistar strain rats (200-220g body weight) obtained from Central Animal House, Rajah Muthiah Medical College, Annamalai University were used in the present study. The rats were fed on pellet diet (Hindustan Lever Limited, Mumbai, India) and water ad libitum. The rats used in the present study were maintained in accordance with the guidelines of the National Institute of Nutrition, Indian Council of Medical Research, Hyderabad, India and the study approved by the ethical committee (Vide. No.285,2005), Annamalai University.

**Experimental Induction of Type 2 Diabetes in Rats**

Non-Insulin dependent diabetes mellitus (NIDDM) was induced in overnight fasted rats by a single intraperitoneal injection of 45 mg/kg streptozotocin, 15 min after the i.p administration of 110 mg/kg body weight of nicotinamide. Streptozotocin (STZ) was dissolved in citrate buffer (pH 4.5) and nicotinamide was dissolved in normal saline. Hyperglycemia was confirmed by the elevated glucose levels in plasma, determined at 72 h and then on day 7 after injection. The rats found with permanent NIDDM were used for the study [15].

**Experimental Procedure**

In the experiment, a total of 42 rats (36 diabetic surviving rats, 6 control rats). Were used the rats were divided into seven groups of six rats each.

- **Group I.** Control rats (salin treated).
- **Group II.** Normal rats administered intraperitoneally with EMS 8 μ mol/g bw for 30 days.
- **Group III.** Diabetic control rats.
- **Group IV.** Diabetic rats administered intraperitoneally with EMS 2 μ mol/g bw for 30 days.
- **Group V.** Diabetic rats administered intraperitoneally with EMS 4 μ mol/g bw for 30 days.
- **Group VI.** Diabetic rats administered intraperitoneally with EMS 8 μ mol/g bw for 30 days.

**Table 1.** Effect of EMS on body weight and food intake in control and experimental rats.

<table>
<thead>
<tr>
<th>Groups</th>
<th>Changes in body weight (g)</th>
<th>Food intake (g/rat per day)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Initial</td>
<td>Final</td>
</tr>
<tr>
<td>Control</td>
<td>186.5±15.8</td>
<td>195.6±16.6***</td>
</tr>
<tr>
<td>Normal + EMS (8 μmol/g)</td>
<td>185.9±13.51</td>
<td>191.6±13.8***</td>
</tr>
<tr>
<td>Diabetic Control</td>
<td>182.4±10.0</td>
<td>160.3±9.6***</td>
</tr>
<tr>
<td>Diabetic + EMS (2 μmol/g)</td>
<td>183.2±10.97</td>
<td>166.3±10.0***</td>
</tr>
<tr>
<td>Diabetic + EMS (4 μmol/g)</td>
<td>184.2±11.0</td>
<td>168.3±10.0***</td>
</tr>
<tr>
<td>Diabetic + Metformin (25mg/kg)</td>
<td>185.2±11.1</td>
<td>192.3±11.5***</td>
</tr>
<tr>
<td>Diabetic + Metformin (25mg/kg)</td>
<td>184.6±11.0</td>
<td>190.1±11.8***</td>
</tr>
</tbody>
</table>

Values are given as mean ± SD from 6 rats in each group. Diabetic control was compared with normal. Experimental groups were compared with the diabetic control group.

* p< 0.05, ** p< 0.01, *** p< 0.001, “ns non significant.

**Table 2.** Effect of EMS on changes in plasma glucose and insulin in Control and experimental rats.

<table>
<thead>
<tr>
<th>Groups</th>
<th>Plasma glucose (mg/dl)</th>
<th>Plasma insulin (μU/mL)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Control</td>
<td>87.13±7.41***</td>
<td>10.51±0.89***</td>
</tr>
<tr>
<td>Normal + EMS (8 μmol/g)</td>
<td>80.77±5.87***</td>
<td>11.31±0.82***</td>
</tr>
<tr>
<td>Diabetic Control</td>
<td>262.28±15.71***</td>
<td>5.20±0.31***</td>
</tr>
<tr>
<td>Diabetic + EMS (2 μmol/g)</td>
<td>141.54±11.0***</td>
<td>7.38±0.57***</td>
</tr>
<tr>
<td>Diabetic + EMS (4 μmol/g)</td>
<td>113.47±8.86***</td>
<td>8.07±0.63***</td>
</tr>
<tr>
<td>Diabetic + EMS (8 μmol/g)</td>
<td>101.72±5.73***</td>
<td>9.67±0.54***</td>
</tr>
<tr>
<td>Diabetic + Metformin (25 mg/kg)</td>
<td>98.50±7.70***</td>
<td>8.96±0.50***</td>
</tr>
</tbody>
</table>

Values are given as mean ± SD from 6 rats in each group. Diabetic control was compared with normal. Experimental groups were compared with the diabetic control group.

* p< 0.05, ** p< 0.01, *** p< 0.001, “ns non significant.
Group VII. Diabetic rats given Metformin 25 mg/kg bw was compared with diabetic control group. *p < 0.05, **p < 0.01, ***p < 0.001, ns non significant.

### Results

#### Body Weight and Food Intake

The changes in the body weight and food intake in control and experimental rats are represented in Table 1. The body weights in EMS and metformin treated diabetic rats increased significantly at the end of the experimental period when compared with diabetic control rats. Food intake significantly increased in diabetic rats and it was significantly reduced in EMS and metformin treated groups compared to diabetic control rats.

#### Plasma Glucose and Insulin Levels

Table 2 demonstrates the level of plasma glucose and insulin in control and experimental animals. The level of plasma glucose was significantly increased whereas plasma insulin was significantly decreased in streptozotocin-nicotinamide diabetic rats. The administration of EMS significantly reversed the changes in a dose dependent manner. EMS at a dose of 8 μmol/g body weight showed a highly significant effect compared to 2 and 4 μmol/g body weight. Administration of EMS was compared with metformin, a references drug. The effect of EMS at a dose 8μmol/g body weights was used for further biochemical analysis.

#### Hemoglobin and Glycosylated Hemoglobin Levels

Table 3 shows the level of hemoglobin and glycosylated hemoglobin of different experimental groups. The diabetic rats showed a significant decrease in the level of total hemoglobin and a significant increase in the level of glycosylated hemoglobin. The administration of EMS and metformin to diabetic rats reversed the changes in total hemoglobin and glycosylated hemoglobin.

#### Liver and Muscle Glycogen Levels

Table 4 shows the changes in the level of liver and muscle glycogen of control and experimental rats. There was a significant reduction in liver and muscle glycogen of STZ-nicotinamide diabetic rats. Administration of EMS and metformin significantly increased the level of glycogen.

---

Table 3: Effect of EMS on changes in the levels of hemoglobin, glycosylated hemoglobin and urine sugar in control and experimental rats.

<table>
<thead>
<tr>
<th>Groups</th>
<th>Hemoglobin (g/dl)</th>
<th>Glycosylated hemoglobin (mg/g Hb)</th>
<th>Urine sugar</th>
</tr>
</thead>
<tbody>
<tr>
<td>Control</td>
<td>11.60±0.68*</td>
<td>0.24±0.02**</td>
<td>Nil</td>
</tr>
<tr>
<td>Normal + EMS (8μmol/g)</td>
<td>12.77±0.87***</td>
<td>0.23±0.01***</td>
<td>Nil</td>
</tr>
<tr>
<td>Diabetic control</td>
<td>7.08±0.60***</td>
<td>0.82±0.05***</td>
<td>+++</td>
</tr>
<tr>
<td>Diabetic + EMS (8μmol/g)</td>
<td>10.90±0.59*</td>
<td>0.35±0.02***</td>
<td>Nil</td>
</tr>
<tr>
<td>Diabetic + Metformin (25 mg/kg)</td>
<td>9.98±0.44*</td>
<td>0.40±0.03*</td>
<td>Trace</td>
</tr>
</tbody>
</table>

Values are given as mean ± SD from 6 rats in each group. Diabetic control was compared with normal. Experimental groups were compared with the diabetic control group.

* p < 0.05, ** p < 0.01, *** p < 0.001, ns non significant.

Table 4: Effect of EMS on changes in the levels of liver and muscle glycogen in control and experimental rats.

<table>
<thead>
<tr>
<th>Groups</th>
<th>Glycogen (mg/g tissue)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Liver</td>
</tr>
<tr>
<td>Control</td>
<td>34.6 ± 2.4*</td>
</tr>
<tr>
<td>Normal + EMS (8μmol/g)</td>
<td>35.7 ± 2.1***</td>
</tr>
<tr>
<td>Diabetic control</td>
<td>23.4 ± 1.8**</td>
</tr>
<tr>
<td>Diabetic + EMS (8μmol/g)</td>
<td>29.5 ± 1.7</td>
</tr>
<tr>
<td>Diabetic + Metformin (25 mg/kg)</td>
<td>26.8 ± 2.3**</td>
</tr>
</tbody>
</table>

Values are given as mean ± SD from 6 rats in each group. Diabetic control was compared with normal. Experimental groups were compared with the diabetic control group.

* p < 0.05, ** p < 0.01, *** p < 0.001, ns non significant.
liver and muscle glycogen.

**Hepatic Carbohydrate Enzymes Levels**

Table 5 shows the changes in the activities of hepatic gluconeogenic enzymes (glucose-6-phosphatase and fructose 1, 6-bisphosphatase), hexokinase, and glucose-6-phosphate dehydrogenase in different experimental groups. The activities of hepatic gluconeogenic enzymes were significantly increased whereas hexokinase and glucose-6-phosphate dehydrogenase were significantly decreased in STZ-nicotinamide diabetic rats. Administration of EMS and metformin to diabetic rats reversed the changes in the activities of these hepatic enzymes to almost control levels.

**DISCUSSION**

The ester of selected carboxylic metabolites, which are mediators in the Krebs cycle or their precursors such as pyruvic acid, succinic acid, and glutamic acid are currently under investigation as potent insulinotropic tools in the treatment of non insulin dependent diabetes [27]. The insulinotropic capacity of succinic acid mono-ethyl ester was first disclosed in pancreatic islets [28]. The nutritional value of this ester when infused to starved rats has been recently documented [29]. The fundamental mechanism underlying hyperglycemia in diabetes mellitus involves over-production (excessive hepatic glycogenolysis and gluconeogenesis) and decreased utilization of glucose by the tissues [30].

The administration of EMS and metformin to decrease the increased blood glucose concentration to normal glycemic concentration is an essential trigger for the liver to revert its normal homeostasis during experimental diabetes. Glucose is metabolized in the pancreatic β cell via glycolysis in the cytosol resulting in pyruvate production. Pyruvate is then transported into the mitochondria for Krebs cycle metabolism supporting subsequent oxidative phosphorylation and ATP production [31-33]. Generation of ATP by increased glucose metabolism promotes a rise in the cytosolic ATP/ADP ratio, closure of the ATP dependent K⁺ channel, opening of the voltage sensitivty Ca²⁺ channels and a subsequent increase in the cytosolic free calcium concentration resulting in triggering of proinsulin synthesis and insulin release [6, 7] promoted by EMS. Metformin reduces fasting plasma glucose level by reducing rates of hepatic glucose production, [34, 35] its effect on the relative contributions of hepatic glycogenolysis [36, 37] and gluconeogenesis [38]. EMS treatment significantly decreases plasma glucose and increases plasma insulin level compared with metformin.

EMS at 8µ mol/g body weight was significantly better than 2 and 4 µmol/g body weight; therefore high dose was used further biochemical studies.

In uncontrolled or poorly controlled diabetes, there is an increased glycation of a number of proteins including hemoglobin and alpha-crystalline of lens [39]. Glycated hemoglobin has been found to be significantly increased in diabetic animals and this increase was directly proportional to fasting blood glucose [40]. Anemia is a much more common disease in type 2 diabetic patients, potentially contributing to the pathogenesis of diabetic complications. Hemoglobin was also recorded as a binary outcome for estimating the risks for anemia [41]. In the present study, the decreased level of hemoglobin indicates the anemia in STZ-nicotinamide diabetic rats. Since during diabetes, the excess glucose transport in the blood reacts with hemoglobin to form glycosyalted hemoglobin. Administration of EMS with metformin controls the glycation of hemoglobin by its normoglycemic activity and thus decreases the level of glycated hemoglobin in STZ-nicotinamide diabetic rats.

In our study, hepatic and skeletal muscle glycogen content was reduced significantly in diabetic controls. Insulin is the main regulator of glycogenesis in muscle and liver. The decrease in hepatic and skeletal muscle glycogen contents in diabetic rats have been observed earlier by Pari and Latha [42]. The decrease in both muscle and hepatic glycogen observed in this study may be due to lack of insulin in the diabetic state and this type of results is probably due to the inactivation of glycogen synthetase system. EMS for 30 days in diabetic rats resulted in a significant elevation of liver and muscle glycogen levels. This shows the one possible way of antidiabeticogenic action of this nonglucidic nutrient may be improvement of glycogenesis process in muscle and liver.

Hexokinase and glucose-6-phosphate dehydrogenase activities have been observed to decrease in STZ diabet-

**Table 5. Effect of EMS on changes in the activities of hepatic hexokinase, glucose-6-phosphate dehydrogenase, glucose-6-phosphatase, and Fructose-1, 6-bisphosphatase in control and experimental rats.**

<table>
<thead>
<tr>
<th>Groups</th>
<th>Control</th>
<th>Normal + EMS (8 µmol/g)</th>
<th>Diabetic control</th>
<th>Diabetic + EMS (8 µmol/g)</th>
<th>Diabetic + Metformin (25 mg/kg)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Hexokinase (units/g protein)</td>
<td>145.2±8.63</td>
<td>152.9±10.50</td>
<td>106.9±6.79</td>
<td>132.0±7.19</td>
<td>126.8±5.60</td>
</tr>
<tr>
<td>Glucose-6-phosphate dehydrogenase (×10⁴ µIU / mg protein)</td>
<td>4.54±0.27</td>
<td>3.92±0.27</td>
<td>2.01±0.12</td>
<td>3.50±0.19</td>
<td>2.89±0.12</td>
</tr>
<tr>
<td>Glucose-6-phosphatase (units/mg protein)</td>
<td>0.12±0.01</td>
<td>0.13±0.01</td>
<td>0.26±0.02</td>
<td>0.16±0.01</td>
<td>0.17±0.01</td>
</tr>
<tr>
<td>Fructose-1,6-bisphosphatase (units/mg protein)</td>
<td>0.29±0.02</td>
<td>0.26±0.01</td>
<td>0.48±0.03</td>
<td>0.36±0.02</td>
<td>0.40±0.03</td>
</tr>
</tbody>
</table>

Values are given as mean ± SD from 6 rats in each group. Diabetic control was compared with normal. Experimental groups were compared with the diabetic control group.

p < 0.05, ***p < 0.01, ****p < 0.001, "n" non significant.

µmoles of glucose phosphorylated/min.
µmoles of Pi liberated/min.
µmoles of Pi liberated/hour
ic rats, which may be due to loss of insulin receptors [43], production of glycated proteins and formation of amadori product [44]. Hexokinase plays an important role in the maintenance of glucose homeostasis and all the cells that metabolize glucose by ATP to produce glucose-6-phosphate. Administration of EMS and metformin to STZ diabetic rats resulted in a significant reversal in the activity of hexokinase.

The activity of glucose-6-phosphate dehydrogenase the first regularey enzyme of pentose phosphate pathway was found to be decreased in diabetic animals [45] and increased in EMS and Metformin treated animals. The activity was higher in comparison to untreated diabetic animals indicating improvement in glucose utilization by this pathway. This may be attributed to the insulin secretory effect of EMS as glucose-6-phosphate dehydrogenase has been reported to increase the supply of NADPH.

The hepatic gluconeogenic enzymes, glucose-6-phosphatase and fructose-1, 6-bisphosphatase were increased significantly in diabetic rats [46] The increased activities of two gluconeogenic enzymes from liver may be due to the activation or increased synthesis of the enzymes contributing to the increased glucose production during diabetes, by liver, and EMS and metformin treatment may be primarily modulating and regulating the activities of the two gluconeogenic enzymes, either through regulation by cyclic AMP and any other metabolic activation or inhibition of glycolysis and gluconeogenesis [47].

Administration of EMS and Metformin significantly decreased the activities of gluconeogenic enzymes in diabetic rats. The level of plasma insulin was found to increase significantly in diabetic rats treated with EMS, which may be a consequence for the significant reduction in the level of gluconeogenic enzymes. The reduction in the activities of gluconeogenic enzymes can result in the decreased concentration of glucose in blood.

In conclusion our result indicate that non-glucidic nutrient EMS possess antidiabetic action. The present investigation draws out a sequential metabolic correlation between increased glycolysis and decreased gluco-neogenesis, increased hydrogen shuttle reaction and normal glycemia stimulated by succinic acid mono ethyl ester, which may have been the biochemical mechanism through which glucose homeostasis is regulated.

**ABBREVIATIONS**

EMS - Succinic acid monoethyl ester  
NIDDM - Non insulin dependent diabetes mellitus  
STZ - Streptozotocin  
bw - Body weight

**REFERENCES**


Pari et al.
Succinic Acid Monoethyl Ester and Metformin Effects in Type 2 Diabetic Rats

34. Christiansen MP, Linfoot PA, Neese RA, Hellerstein M. Metformin effects upon post absorptive intra hepatic carbohydrate fluxes. Diabetes 1997;46:244A.
42. Christiansen MP, Linfoot PA, Neese RA, Hellerstein M. Metformin effects upon post absorptive intra hepatic carbohydrate fluxes. Diabetes 1997;46:244A.
49. Christiansen MP, Linfoot PA, Neese RA, Hellerstein M. Metformin effects upon post absorptive intra hepatic carbohydrate fluxes. Diabetes 1997;46:244A.

Address correspondence to: Dr. L Pari, Department of Biochemistry and Biotechnology, Faculty of Science, Annamalai University, Annamalai Nagar-608 002, Tamil Nadu, India. Tel: + 91 4144 238343, Fax: + 91 4144 238145. E-mail: pariba- laji@gmail.com